德视佳宣布加码布局欧洲屈光手术市场。公司公布,其全资附属公司EuroEyesSwiss已与BetterviewSwiss达成协议,计划以1201万瑞士法郎(折合约1.17亿港元)收购瑞士资产。该交易于2025年9月2日正式订立,旨在进一步拓展德视佳在欧洲的眼科业务版图。
德视佳宣布加码布局欧洲屈光手术市场。公司公布,其全资附属公司EuroEyesSwiss已与BetterviewSwiss达成协议,计划以1201万瑞士法郎(折合约1.17亿港元)收购瑞士资产。该交易于2025年9月2日正式订立,旨在进一步拓展德视佳在欧洲的眼科业务版图。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.